Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration

Clinical Chemistry

Volumn 62, Issue 1, 2016, Pages 243-251

  Robert Bergen, H ^a   Dasari, Surendra ^b   Dispenzieri, Angela ^b   Mills, John R ^b   Ramirez Alvarado, Marina ^a   Tschumper, Renee C ^a   Jelinek, Diane F ^a   Barnidge, David R ^b   Murray, David L ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

M PROTEIN; MESSENGER RNA; COMPLEMENTARITY DETERMINING REGION; IMMUNOGLOBULIN LIGHT CHAIN; PEPTIDE;

ARTICLE; BLOOD SAMPLING; BONE MARROW BIOPSY; FLOW CYTOMETRY; HUMAN; LIGHT CHAIN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETER; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; SEQUENCE ALIGNMENT; TANDEM MASS SPECTROMETRY; BLOOD; BONE MARROW; BONE MARROW EXAMINATION; COMPLEMENTARITY DETERMINING REGION; GENETICS; NEOPLASM, RESIDUAL; PATHOLOGY; SUCTION;

BONE MARROW; BONE MARROW EXAMINATION; COMPLEMENTARITY DETERMINING REGIONS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PEPTIDES; RNA, MESSENGER; SUCTION;

EID: 84954514483     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.242651     Document Type: Article

References (29)

1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
3. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
4. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
5. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017-23.
6. Ladetto M, Bruggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2014;28:1299-307.
7. Hart AJ, Jagasia MH, Kim AS, Mosse CA, Savani BN, Kassim A. Minimal residual disease in myeloma: are we there yet? Biol Blood Marrow Transplant 2012;18:1790-9.
8. Cavo M, Terragna C, Martinelli G, Ronconi S, Zamagni E, Tosi P, et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000;96:355-7.
9. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000;18:2273-81.
10. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli R, et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 2000;85:930-4.
11. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999;17:208-15.
12. Swedin A, Lenhoff S, Olofsson T, Thuresson B, Westin J. Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma. Br J Haematol 1998;103:1145-51.
13. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 1995;15:367-71.
14. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995;85:1596-602.
15. Sarasquete ME, Garcia-Sanz R, Gonzalez D, Martinez J, Mateo G, Martinez P, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005;90:1365-72.
16. Hadzidimitriou A, Stamatopoulos K, Belessi C, Lalayianni C, Stavroyianni N, Smilevska T, et al. Immunoglobulin genes in multiple myeloma: expressed and nonexpressed repertoires, heavy and light chain pairings and somatic mutation patterns in a series of 101 cases. Haematologica 2006;91:781-7.
17. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX study. J Clin Oncol 2013;31:2540-7.
18. Dekker LJ, Zeneyedpour L, Brouwer E, van Duijn MM, Sillevis Smitt PA, Luider TM. An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions. Anal Bioanal Chem 2011;399:1081-91.
19. Remily-Wood ER, Benson K, Baz RC, Chen YA, Hussein M, Hartley-Brown MA, et al. Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients. Proteomics Clin Appl 2014;8:783-95.
20. Barnidge DR, Tschumper RC, Theis JD, Snyder MR, Jelinek DF, Katzmann JA, et al. Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS. J Proteome Res 2014;13:1905-10.
21. Barnidge DR, Dasari S, Botz CM, Murray DH, Snyder MR, Katzmann JA, et al. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J Proteome Res 2014;13:1419-27.
22. Dasari S, Theis JD, Vrana JA, Meureta OM, Quint PS, Muppa P, et al. Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies. J Proteome Res 2015;14:1957-67.
23. Ehrenmann F, Kaas Q, Lefranc MP. IMGT/3Dstructure-DB and IMGT/Domain GapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IGSF and MHCSF. Nucleic Acids Res 2010;38:D301-7.
24. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-quest: the highly customized and integrated system for Ig and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008;36:W503-8.
25. Morice WG, Hanson CA, Kumar S, Frederick LA, Lesnick CE, Greipp PR. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia 2007;21:2043-6.
26. Song MK, Chung JS, Lee JJ, Min CK, Ahn JS, Lee SM, et al. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation. Br J Haematol 2014;165:777-85.
27. Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B, et al. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica 2013;98:71-8.
28. Rubin R. Precision medicine: the future or simply politics? JAMA 2015;313:1089-91.
29. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957-9.